Physiologically based pharmacokinetic (PBPK) modeling is less well established for substrates of UDP-glucuronosyltransferases (UGT) than for cytochrome P450 (CYP) metabolized drugs and more verification of simulations is necessary to increase confidence. To address specific challenges of UGT substrates, we developed PBPK models for four drugs cleared majorly via glucuronidation (lorazepam, oxazepam, naloxone, and zidovudine). In vitro to in vivo scaling of intrinsic clearance generated with co-cultured human hepatocytes was applied for hepatic metabolism and extra-hepatic clearance was extrapolated based on relative expression of UGT isoforms in the liver, kidney, and intestine. Non-metabolic clearance and the contributions of individual UGT isoforms to glucuronidation were based on in vitro and in vivo studies taken from the literature and simulations were verified and evaluated with a broad set of clinical pharmacokinetic data. Model evaluation showed systemic clearance predictions within 1.5-fold for all drugs and all simulated parameters were within 2-fold of observed. However, during the verification step, top-down model fitting was necessary to adjust for under-prediction of zidovudine VSS and renal clearance and over estimation of intestinal first pass for lorazepam, oxazepam, and zidovudine. The impact of UGT2B15 polymorphisms on the pharmacokinetics of oxazepam and lorazepam was simulated and glucuronide metabolites were also simulated for all four drugs. To increase confidence in predicting extra-hepatic clearance, improvement of enzyme phenotyping for UGT substrates and more quantitative tissue expression levels of UGT enzymes are both needed. Prediction of glucuronide disposition is also challenging when active transport processes play a major role.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Area under the plasma concentration-time curve
- CLint :
Concentrative nucleoside transporter
- C max :
Equilibrative nucleoside transporter
- F :
- F a :
Fraction of the drug entering the enterocytes
- FDp :
Fraction of the drug reaching the portal vein
- F G :
Fraction of the drug that escapes gut metabolism
- F H :
Fraction of the drug that escapes hepatic first-pass metabolism
- f m :
- f u,ent :
Fraction unbound in enterocytes
- f u,inc :
Fraction unbound in incubation
- f u,p :
Fraction unbound in plasma
Glomerular filtration rate
Inter-system extrapolation factor
- K p :
Tissue:plasma partition coefficients
New drug applications
Organic anion transporter
Organic cation transporter
- PBPK modeling:
Physiologically based pharmacokinetic modeling
Parameter sensitivity analysis
Relative activity factor
- T max :
Time of peak concentration
Recombinant human UGT
- V SS :
Volume of distribution at steady state
Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol. 2013;2:e63.
Grimstein M, Yang Y, Zhang X, Grillo J, Huang SM, Zineh I, et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration’s Office of Clinical Pharmacology. J Pharm Sci. 2019;108(1):21–5.
Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97(3):247–62.
Ohno S, Nakajin S. Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos. 2009;37(1):32–40.
Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 2013;45(6):1121–32.
Argikar UA, Potter PM, Hutzler JM, Marathe PH. Challenges and opportunities with non-CYP enzymes aldehyde oxidase, carboxylesterase, and UDP-glucuronosyltransferase: focus on reaction phenotyping and prediction of human clearance. AAPS J. 2016;18(6):1391–405.
Cerny MA. Prevalence of non–cytochrome P450–mediated metabolism in Food and Drug Administration–approved oral and intravenous drugs: 2006–2015. Drug Metab Disposition. 2016;44(8):1246–52.
Lv X, Zhang J-B, Hou J, Dou T-Y, Ge G-B, Hu W-Z, et al. Chemical probes for human UDP-glucuronosyltransferases: a comprehensive review. Biotechnol J. 2019;14(1):1800002.
Zientek MA, Youdim K. Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes. Drug Metab Dispos. 2015;43(1):163–81.
Achour B, Rostami-Hodjegan A, Barber J. Protein expression of various hepatic uridine 5′-diphosphate glucuronosyltransferase (UGT) enzymes and their inter-correlations: a meta-analysis. Biopharm Drug Dispos. 2014;35(6):353–61.
Margaillan G, Rouleau M, Fallon JK, Caron P, Villeneuve L, Turcotte V, et al. Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues. Drug Metab Disposition. 2015;43(4):611–9.
Couto N, Al-Majdoub Z, Gibson S, Davies P, Achour B, Harwood MD, et al. Quantitative proteomics of clinically relevant drug-metabolizing enzymes and drug transporters and their inter-correlations in the human small intestine. Drug Metab Disposition. 2020. https://doi.org/10.1124/dmd.119.089656.
Zhuang X, Lu C. PBPK modeling and simulation in drug research and development. Acta Pharm Sin B. 2016;6(5):430–40.
Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL, et al. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos. 2002;30(11):1257–65.
Uchaipichat V, Suthisisang C, Miners JO. The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs. Drug Metab Disposition. 2013;41(6):1273–84.
Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, et al. 3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos. 2000;28(5):497–502.
Di Marco A, D’Antoni M, Attaccalite S, Carotenuto P, Laufer R. Determination of drug glucuronidation and UDP-glucuronosyltransferase selectivity using a 96-well radiometric assay. Drug Metab Dispos. 2005;33(6):812–9.
Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. Nat Biotechnol. 2007;26:120.
Da-Silva F, Boulenc X, Vermet H, Compigne P, Gerbal-Chaloin S, Daujat-Chavanieu M, et al. Improving prediction of metabolic clearance using quantitative extrapolation of results obtained from human hepatic micropatterned cocultures model and by considering the impact of albumin binding. J Pharm Sci. 2018;107(7):1957–72.
Lin C, Shi J, Moore A, Khetani SR. Prediction of drug clearance and drug-drug interactions in microscale cultures of human hepatocytes. Drug Metab Dispos. 2016;44(1):127–36.
Wood FL, Houston JB, Hallifax D. Clearance prediction methodology needs fundamental improvement: trends common to rat and human hepatocytes/microsomes and implications for experimental methodology. Drug Metab Dispos. 2017;45(11):1178–88.
Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet. 1981;6(2):89–105.
Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018;9(1):63–88.
Langtry HD, Campoli-Richards DM. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989;37(4):408–50.
Popovic GV, Sladic DM, Stefanovic VM, Pfendt LB. Study on protolytic equilibria of lorazepam and oxazepam by UV and NMR spectroscopy. J Pharm Biomed Anal. 2003;31(4):693–9.
Wermeling DP. A response to the opioid overdose epidemic: naloxone nasal spray. Drug Delivery and Translational Research. 2013;3(1):63–74.
Gennaro AR. Remington: the science and practice of pharmacy. 19th Edition ed: Mack Publishing, Easton 1995.
Pyka A, Babuska M, Zachariasz M. A comparison of theoretical methods of calculation of partition coefficients for selected drugs. Acta Pol Pharm. 2006;63(3):159–67.
D.B. Turner, D Pade, M. Jamei, S. Neuhof. A mechanistic physiologically-based pharmacokinetic (PBPK) model to predict the pharmacokinetics of R/S-oxazepam after oral dosing.
Villard A-L, Coussot G, Lefebvre I, Augustijns P, Aubertin A-M, Gosselin G, et al. Phenyl phosphotriester derivatives of AZT: variations upon the SATE moiety. Biorg Med Chem. 2008;16(15):7321–9.
Hadžiabdić J, Elezovic A, Imamović B, Becic E. The improvement of lorazepam solubility by cosolvency, micellization and complexation. Jordan J Pharm Sci. 2012;5(2):141–54
Nakano M, Kohri N, Arakawa Y, Arita T. The permeation of benzodiazepines through synthetic membranes. Chem Pharm Bull (Tokyo). 1979;27(3):573–7.
Dezani AB, Pereira TM, Caffaro AM, Reis JM, Serra CHR. Equilibrium solubility versus intrinsic dissolution: characterization of lamivudine, stavudine and zidovudine for BCS classification. Brazilian Journal of Pharmaceutical Sciences. 2013;49:853–63.
Li C, Liu T, Cui X, Uss AS, Cheng KC. Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans. J Biomol Screen. 2007;12(8):1084–91.
Dezani AB, Pereira TM, Caffaro AM, Reis JM, Serra CH. Determination of lamivudine and zidovudine permeability using a different ex vivo method in Franz cells. J Pharmacol Toxicol Methods. 2013;67(3):194–202.
Brown HS, Griffin M, Houston JB. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos. 2007;35(2):293–301.
Mistry M, Houston JB. Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metab Dispos. 1987;15(5):710–7.
Luzier A, Morse GD. Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. Antivir Res. 1993;21(3):267–80.
Greenblatt DJ, Schillings RT, Kyriakopoulos AA, Shader RI, Sisenwine SF, Knowles JA, et al. Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam. Clin Pharmacol Ther. 1976;20(3):329–41.
Sonne J, Loft S, Døssing M, Vollmer-Larsen A, Olesen KL, Victor M, et al. Bioavailability and pharmacokinetics of oxazepam. Eur J Clin Pharmacol. 1988;35(4):385–9.
Veal GJ, Back DJ. Metabolism of zidovudine. Gen Pharmacol. 1995;26(7):1469–75.
Suzuki T, Ohmuro A, Miyata M, Furuishi T, Hidaka S, Kugawa F, et al. Involvement of an influx transporter in the blood-brain barrier transport of naloxone. Biopharm Drug Dispos. 2010;31(4):243–52.
Errasti-Murugarren E, Pastor-Anglada M. Drug transporter pharmacogenetics in nucleoside-based therapies. Pharmacogenomics. 2010;11(6):809–41.
Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002;300(3):918–24.
Patel M, Tang BK, Grant DM, Kalow W. Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. Pharmacogenetics. 1995;5(5):287–97.
Manevski N, Moreolo PS, Yli-Kauhaluoma J, Finel M. Bovine serum albumin decreases km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9. Drug Metab Disposition. 2011;39(11):2117–29.
Harbourt DE, Fallon JK, Ito S, Baba T, Ritter JK, Glish GL, et al. Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. Anal Chem. 2012;84(1):98–105.
Nishimura M, Ejiri Y, Kishimoto S, Suzuki S, Satoh T, Horie T, et al. Expression levels of drug-metabolizing enzyme, transporter, and nuclear receptor mRNAs in a novel three-dimensional culture system for human hepatocytes using micro-space plates. Drug Metab Pharmacokinet. 2011;26(2):137–44.
Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos. 2012;40(1):83–92.
Heikkinen AT, Baneyx G, Caruso A, Parrott N. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus. Eur J Pharm Sci. 2012;47(2):375–86.
Abduljalil K, Cain T, Humphries H, Rostami-Hodjegan A. Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. Drug Metab Disposition. 2014;42(9):1478–84.
Klecker RW Jr, Collins JM, Yarchoan R, Thomas R, Jenkins JF, Broder S, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987;41(4):407–12.
Chatton JY, Munafo A, Chave JP, Steinhauslin F, Roch-Ramel F, Glauser MP, et al. Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. Br J Clin Pharmacol. 1992;34(6):551–4.
Ladumor MK, Thakur A, Sharma S, Rachapally A, Mishra S, Bobe P, et al. A repository of protein abundance data of drug metabolizing enzymes and transporters for applications in physiologically based pharmacokinetic (PBPK) modelling and simulation. Sci Rep. 2019;9(1):9709.
Greenblatt DJ, Comer WH, Elliott HW, Shader RI, Knowles JA, Ruelius HW. Clinical pharmacokinetics of lorazepam. III. Intravenous injection. Preliminary results. J Clin Pharmacol. 1977;17(8–9):490–4.
Greenblatt DJ, Murray TG, Audet PR, Locniskar A, Koepke HH, Walker BR. Multiple-dose kinetics and dialyzability of oxazepam in renal insufficiency. Nephron. 1983;34(4):234–8.
Patwardhan RV, Yarborough GW, Desmond PV, Johnson RF, Schenker S, Speeg KV Jr. Cimetidine spares the glucuronidation of lorazepam and oxazepam. Gastroenterology. 1980;79(5 Pt 1):912–6.
Smink BE, Hofman BJ, Dijkhuizen A, Lusthof KJ, de Gier JJ, Egberts AC, et al. The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam. Br J Clin Pharmacol. 2008;66(4):556–60.
van Hecken AM, Tjandramaga TB, Verbesselt R, de Schepper PJ. The influence of diflunisal on the pharmacokinetics of oxazepam. Br J Clin Pharmacol. 1985;20(3):225–34.
Dong J, Liu S, Zhang H, Hua Q, Zhao X, Miao L. Determination of naloxone-3-glucuronide in human plasma and urine by HILIC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;942–943:83–7.
Kongstad KT, Papathanasiou T, Springborg AD, Lund TM, Werner MU, Staerk D. Simultaneous quantification of high-dose naloxone and naloxone-3-beta-d-glucuronide in human plasma by UHPLC-MS/MS. Bioanalysis. 2019;11:165–73.
Lertora JJ, Rege AB, Greenspan DL, Akula S, George WJ, Hyslop NE Jr, et al. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 1994;56(3):272–8.
He X, Hesse LM, Hazarika S, Masse G, Harmatz JS, Greenblatt DJ, et al. Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol. 2009;68(5):721–30.
Chung JY, Cho JY, Yu KS, Kim JR, Jung HR, Lim KS, et al. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005;77(6):486–94.
Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med. 1995;333(18):1171–5.
Caillier B, Lépine J, Tojcic J, Ménard V, Perusse L, Bélanger A, et al. A pharmacogenomics study of the human estrogen glucuronosyltransferase UGT1A3. Pharmacogenet Genomics. 2007;17(7):481–95.
Lévesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther. 2007;81(3):392–400.
Yuan L-M, Gao Z-Z, Sun H-Y, Qian S-N, Xiao Y-S, Sun L-L, et al. Inter-isoform hetero-dimerization of human UDP-glucuronosyltransferases (UGTs) 1A1, 1A9, and 2B7 and impacts on glucuronidation activity. Sci Rep. 2016;6:34450.
Pastor-Anglada M, Pérez-Torras S. Emerging roles of nucleoside transporters. Front Pharmacol. 2018;9:606.
Docci L KF, Ekiciler A, Molitor B, Umehara K, Walter I, Krähenbühl S, Parrott NJ, Fowler S. In vitro to in vivo extrapolation of metabolic clearance for UGT substrates using short-term suspension and long-term co-cultured human hepatocytes. Accepted for publication in AAPSJ 2020.
Horiuchi K, Ohnishi S, Matsuzaki T, Funaki S, Watanabe A, Mizutare T, et al. Improved human pharmacokinetic prediction of hepatically metabolized drugs with species-specific systemic clearance. J Pharm Sci. 2018;107(5):1443–53.
Kim CH, An H, Kim SH, Shin D. Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects. Drug Des Devel Ther. 2017;11:3461–9.
Maharaj AR, Barrett JS, Edginton AN. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J. 2013;15(2):455–64.
Ye M, Nagar S, Korzekwa K. A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding. Biopharm Drug Dispos. 2016;37(3):123–41.
Jiunn HL, Bradley KW. Complexities of glucuronidation affecting in vitro-in vivo extrapolation. Curr Drug Metab. 2002;3(6):623–46.
Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Disposition. 2004;32(11):1201–8.
Morris RG, Black AB, Lam E, Westley IS. Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage? Ther Drug Monit. 2000;22(6).
Naesens M, Kuypers DRJ, Streit F, Armstrong VW, Oellerich M, Verbeke K, et al. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther. 2006;80(5):509–21.
Oda S, Fujiwara R, Kutsuno Y, Fukami T, Itoh T, Yokoi T, et al. Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast. Drug Metab Disposition. 2015;43(6):812–8.
Umehara KI, Huth F, Gu H, Schiller H, Heimbach T, He H. Estimation of fractions metabolized by hepatic CYP enzymes using a concept of inter-system extrapolation factors (ISEFs) - a comparison with the chemical inhibition method. Drug Metab Pers Ther. 2017;32(4):191–200.
Knights KM, Spencer SM, Fallon JK, Chau N, Smith PC, Miners JO. Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance. Br J Clin Pharmacol. 2016;81(6):1153–64.
Sato Y, Nagata M, Tetsuka K, Tamura K, Miyashita A, Kawamura A, et al. Optimized methods for targeted peptide-based quantification of human uridine 5′-diphosphate-glucuronosyltransferases in biological specimens using liquid chromatography-tandem mass spectrometry. Drug Metab Dispos. 2014;42(5):885–9.
Zhang H, Wolford C, Basit A, Li AP, Fan PW, Takahashi RH, et al. Regional proteomic quantification of clinically relevant non-cytochrome P450 enzymes along the human small intestine. Drug Metab Disposition. 2020. https://doi.org/10.1124/dmd.120.090738.
Mizuma T. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm. 2009;378(1):140–1.
Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther. 2012;50(5):360–7.
Miyauchi E, Tachikawa M, Decleves X, Uchida Y, Bouillot JL, Poitou C, et al. Quantitative atlas of cytochrome P450, UDP-glucuronosyltransferase, and transporter proteins in jejunum of morbidly obese subjects. Mol Pharm. 2016;13(8):2631–40.
Ge S, Wei Y, Yin T, Xu B, Gao S, Hu M. Transport-glucuronidation classification system and PBPK modeling: new approach to predict the impact of transporters on disposition of glucuronides. Mol Pharm. 2017;14(9):2884–98.
Kimoto E, Li R, Scialis RJ, Lai Y, Varma MV. Hepatic disposition of gemfibrozil and its major metabolite gemfibrozil 1-O-beta-glucuronide. Mol Pharm. 2015;12(11):3943–52.
Nguyen HQ, Callegari E, Obach RS. The use of in vitro data and physiologically-based pharmacokinetic modeling to predict drug metabolite exposure: desipramine exposure in cytochrome P4502D6 extensive and poor metabolizers following administration of imipramine. Drug Metab Dispos. 2016;44(10):1569–78.
Obach RS, Lin J, Kimoto E, Duvvuri S, Nicholas T, Kadar EP, et al. Estimation of circulating drug metabolite exposure in human using in vitro data and physiologically based pharmacokinetic modeling: example of a high metabolite/parent drug ratio. Drug Metab Dispos. 2018;46(2):89–99.
van Dorp EL, Morariu A, Dahan A. Morphine-6-glucuronide: potency and safety compared with morphine. Expert Opin Pharmacother. 2008;9(11):1955–61.
Pumford NR, Myers TG, Davila JC, Highet RJ, Pohl LR. Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. Chem Res Toxicol. 1993;6(2):147–50.
Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet. 2002;41(10):751–90.
Wu B. Use of physiologically based pharmacokinetic models to evaluate the impact of intestinal glucuronide hydrolysis on the pharmacokinetics of aglycone. J Pharm Sci. 2012;101(3):1281–301.
Li R, Ghosh A, Maurer TS, Kimoto E, Barton HA. Physiologically based pharmacokinetic prediction of telmisartan in human. Drug Metab Disposition. 2014;42(10):1646–55.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic Supplementary Material
About this article
Cite this article
Docci, L., Umehara, K., Krähenbühl, S. et al. Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine. AAPS J 22, 128 (2020). https://doi.org/10.1208/s12248-020-00513-5
- in vitro to in vivo extrapolation
- intestinal metabolism
- physiologically based pharmacokinetics
- renal metabolism